functional capacity nor objective performance on cardiopulmonary exercise testing predisposed patients to cardiovascular complications. Regardless, the Duke Activity Status Index (DASI) score hap pened to confer a higher risk, which was significant (adjusted odds ratio 0•96, 95% CI 0•83-0•99; p=0•03). Although the authors highlighted this discrepancy, a chance of a type II error in calculation of risk using the DASI score was not mentioned. This omission is pertinent given the somewhat tenuous risk association of DASI, with an upper confidence interval that approaches 1•00. Primarily, this trial demonstrates that subjective and objective functional performance does not predict the occurrence of adverse cardiovascular events. Based on the weight of the evidence in the study, it might be premature to infer that the DASI could be the suitable replacement for clinical subjective assessment of functional capacity.
Second, it is notable that ten (41%) of 24 myocardial infarction events occurred in patients with a clinically significant postoperative complication. It would be of interest to assess whether significant differences existed in the results of preoperative functional exercise testing between the myocardial infarction cohorts with and without a postoperative complication. The variable performance of preoperative risk stratification tools and functional status might reflect the pathophysiological heterogeneity that underpins perioperative cardiovascular complications.
2 Therefore, future development of models of risk prediction that integrate putative risk factors, biomarkers, and non-invasive imaging are essential.
We declare no competing interests. We commend Duminda Wijeysundera and colleagues 1 for testing the prognostic value conferred by assessment of subjective functional capacity in non-cardiac surgery and read the results with interest. We raise two issues with the published data.
Anoop
First, the investigators reported that neither assessment of subjective
Authors' reply
We thank the correspondents for their interest in our study. Ganesan Karthikeyan raises concerns about our analytic approach and potential misclassification of subjectively assessed functional capacity. He is correct that the low number of primary outcome events (death or myocardial infarction within 30 days of surgery) in our study limits the statistical power of our analysis. Although the proportion of patients with these events was consistent with another study on elective non-cardiac surgery, 2 we do clearly acknowledge this limitation in our Article. Despite this limitation, our analysis did adjust for important risk factors when calculating Revised Cardiac Risk Index (RCRI) scores. The RCRI includes high-risk surgery but not advanced age, which is often excluded from guideline algorithms. 3, 4 Additionally, the results of our secondary analysis of more frequent cardiovascular endpoints (30-day death or myocardial injury), which adjusted for more risk factors (ie, age, sex, and RCRI), produced similar results to our primary analysis. Although inclusion of highly correlated covariates in regression models might indeed lead to multicollinearity, this issue does not affect our analyses of predictive performance of preoperative func tional capacity measures because the principal exposures (Duke Activity Status Index [DASI], plasma concentrations of N-terminal pro-B-type natriuretic peptide, and mean peak oxygen consumption) were evaluated in separate models with otherwise similar covariates. Karthikeyan also raised concerns about categorising participants as having poor functional capacity if anaesthesiologists reported drugs and should join forces in this area.
Rare diseases cannot continue to be neglected in developing countries, and international collaboration among these countries is vital to change the situation. Screening programmes should be introduced for more diseases, and educational programmes for doctors (especially paediatricians and general practitioners) and nurses should be implemented; these would raise the number of diagnoses and reduce misdiagnoses. Most importantly, more patients with rare diseases for which drugs are available should be treated.
Legislations, regulations, and policies for orphan drugs should be drafted and implemented (a review article 3 failed to identify any pertinent legislation in Latin American and African countries). Patient organisations should be created in LMICs and should play a prominent role in increasing awareness and urging governments to provide treatment for rare diseases, particularly for children. Provision of antiretrovirals to HIV-infected patients in LMICs was considered impossible on economic grounds 20 years ago, and became a reality in 2010; a joint effort from patient organisations and governments could make the provision of orphan drugs to patients in need in the same countries a reality.
We declare no competing interests. For all these reasons, we believe Karthikeyan's final statement to be markedly overstated. Indeed, the consistently poor performance of subjective assessment in predicting outcomes identifies the need for better approaches towards preoperative risk evaluation. Anoop Koshy and colleagues raise concerns about whether our results support the incorporation of the DASI questionnaire in preoperative risk assessment. We certainly agree that further validation of the DASI is needed in the perioperative setting. In the interim, our findings are sufficiently robust to support replacing subjective assessment with the DASI questionnaire during preoperative evaluation. The questionnaire demonstrated prognostic utility in the study cohort across two cardiovascular endpoints and two statistical measures (net risk reclassification index and logistic regression model coefficients).
*Francesca Cainelli, Sandro Vento
We agree with Jairo Dussán-Sarria and colleagues that tools for estimating simple bedside risk have the potential to improve patient care. However, the METS study did not seek to develop such a tool; rather, its narrower focus was to identify optimal approaches for using preoperative functional capacity to inform risk estimation. The METS study thus complements work done by Stefani and colleagues, 5 because it identifies the optimal measures of functional capacity that might be included in indices of risk stratification.
Orphan drugs
Lucio Luzzatto and colleagues 1 (Sept 1, 2018, p 791) have called for collaboration from EU member states on negotiation of orphan drug prices to take advantage of the fact that with 500 million inhabitants, the EU is the largest customer for any new drug. Low-income and middle-income countries (LMICs), with more than 6 billion inhabitants and 360-480 million patients with rare diseases, 2 are in need of orphan
